



Dedicated to Saving Lives
by Transforming At-home
Cancer Detection

Investor Presentation October 2025

Safe Harbor

This presentation may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those concerning our expectations, anticipations, intentions, beliefs or strategies regarding the future. We intend all forward-looking statements to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on assumptions that we have made as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions and events to differ materially from those anticipated. Therefore, you should not place undue reliance on forward-looking statements. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results; expectations for development of new or improved products and services; our strategies, positioning, resources, capabilities and expectations for future events or performance; and the anticipated benefits of our acquisitions, including estimated synergies and other financial impacts.

Mainz Biomed N.V (the “Company”) assumes no obligation to update forward-looking statements as circumstances change, except as required by law. Investors are advised to consult further disclosures that the Company makes or has made on related subjects in the Company's most recent periodic reports filed with the Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent reports on Form 6-K filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. This presentation does not constitute an offer to sell or a solicitation of an offer to buy securities in any potential transaction, nor shall there be any offer, solicitation, or sale of any such securities in any jurisdiction, or to whom any person, where such offer, solicitation, or sale would be unlawful. Before making an investment decision, potential investors should undertake their own due diligence regarding the Company and consult their own legal, tax, accounting, and other professional advisers.



Mainz BioMed Overview



Colorectal cancer screening presents a significant opportunity in the molecular diagnostics market.

- US annual market > \$30bn by 2032¹
- 3rd most-commonly diagnosed cancer²
- 2nd leading cause of cancer death globally²
- Ability to move into large, adjacent areas, including pancreatic cancer and other GI cancers



Developing novel standard for non-invasive detection of AA in development

- Early detection of advanced adenomas (precancerous lesions) could drastically reduce or even eliminate cancer
- Strong clinical performance shown with two independent studies with CRC sensitivities above 90% and AA sensitivities above 80%



Disruptive, decentralized business model

- Kit-based solution that allows the testing to be done in any lab across the United States.
- All competitors using CLIA laboratory based centralized solutions that require large investments to broadly commercialize the product nationally
- Enables the sale of ColoAlert® internationally



First Generation CRC screening test launched in Europe (ColoAlert®)

- Highly efficacious, at-home, stool-based screening test for early colorectal cancer (CRC) detection
- Combines a FIT test for detection of human hemoglobin with the PCR results of specific tumor DNA markers
- Marketed as a CE-IVD product in Europe since 2021



Strong team

- Experienced diagnostics team, formerly Roche, Abbott or Qiagen; took the company public in 2021
- 25 employees with headquarters in Mainz, Germany
- Strong Medical Advisory Board with renowned scientific and oncology experts



Next-generation Pancreatic Cancer Detection

- Partnered with Liquid Biosciences to develop the next-generation detection test for pancreatic cancer
- We have entered into a license and option agreement to access novel mRNA biomarkers for early detection of pancreatic cancer via blood test
- Independent validation of the algorithm-biomarker combination showed 95% sensitivity and 98% specificity

¹ Global Market Insights ² <https://www.who.int/news-room/fact-sheets/detail/cancer>

Recent Developments – Agreements with Thermo Fisher and Quest



ThermoFisher
SCIENTIFIC

- Thermo Fisher Scientific Inc. (NYSE: TMO; Market Cap¹: \$202.58B) is in serving science, with annual revenue over \$40 billion
- Mainz Biomed entered into a Collaboration Agreement with Thermo Fisher Scientific in November 2024
- Mainz intends to develop its Next Generation assays on the Thermo Fisher Extraction (King Fisher) and PCR (QuantStudio) platforms; Thermo Fisher will contribute development resources to the partnership
- Thermo Fisher is providing Extraction and PCR instrumentation and consumables during development at significant discounts to market




- Quest Diagnostics (NYSE: DGX; Market Cap¹: \$18.16B), with revenue over \$9 billion in 2023, is a national reference lab serving one out of every three adult patients in the U.S.
- Mainz also entered into Agreements with Quest Diagnostics in November 2024
- Quest will be a lab partner for our pivotal study and will have a semi-exclusive distributor option right in the U.S. for eighteen months from the time of our FDA PMA

¹ Market Cap as of November 26, 2024 sourced from Capital IQ

Early Identification of Colorectal Cancer (CRC) Saves Lives

Clinical progression from colorectal polyp to cancer




The goal of Mainz Biomed's next generation screening test is to improve the detection of advanced adenomas (precancerous lesions)

- Almost all colorectal cancers develop from polyps over time
- With increasing time of a polyp being present, the risk of malignancy increases
- Early screening has the potential to dramatically impact the treatment and prevention of CRC, and ultimately save lives
- In a screening population ≥ 45 :
 - 21% sensitivity for adenomas would reduce mortality from CRC by 47%¹
 - 76% sensitivity for adenomas would reduce mortality from CRC by 67%¹

¹ Ladabaum U, et al. Counting Advanced Precancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity. JNCI: Journal of the National Cancer Institute, Volume 114, Issue 7, July 2022, Pages 1040-1043 <https://doi.org/10.1093/jnci/djac027>

Our Current Flagship Product – ColoAlert®

A PCR based CRC early detection stool test: simple, fast, accurate and non-invasive



- Highly accurate test (**92% specificity, 85% sensitivity**)¹
- 98% patient satisfaction – easy product to use²
- Designed to offer affordable CRC screening solutions
- Identifies tumor DNA next to blood in stool samples
- Fast result turnaround time (3d after sample receipt)



DNA stabilization tube



FIT tube




¹ Published by: Dollinger MM et al. Clin Lab 10/2018

² 98% overall satisfaction with ColoAlert® in our internal customer survey.

Next Generation Screening Test – mRNA Biomarkers & FIT

Combination of mRNA biomarkers & FIT creating leading product for AA and CRC detection




mRNA Biomarkers are effective in detecting advanced adenomas



- mRNA testing can detect molecular changes in cells even before visible abnormalities or symptoms manifest
- mRNA biomarkers reflect the dynamic changes in gene expression that occur during the progression of adenomas to advanced stages. As adenomas evolve, certain genes may be upregulated or downregulated, and RNA biomarkers can capture these changes, providing insights into the stage of adenoma development
- mRNA biomarkers are highly specific to particular stages or types of adenomas. By targeting RNA molecules associated with the advanced stage of adenomas, these biomarkers can distinguish between advanced adenomas and less advanced forms or benign conditions
- mRNA biomarkers sensitivity allows for the detection of even small quantities of RNA molecules associated with advanced adenomas. This sensitivity enables the detection of adenomas at early stages
- mRNA expression pattern changes can be used as an early predictor for the onset of a certain disease

Next Generation Test: Clinical Validation and Trials

Study name	Patient population type	Study size	Study location
ColoFuture	Enriched	436	EU
eAArly Detect	Enriched	254	US
Pooled study	Enriched	690	EU & US
eAArly Detect v2	Average risk	2,000	US
reconAAsense	Average risk	15,000	US




Next Generation Test: Clinical Validation and Trials


Study name	Patient population type	Study size	Study location	CRC sensitivity	CRC specificity	AA sensitivity	AA specificity
ColoFuture	Enriched	436	EU	94%	97%	80%	95%
eAArly Detect	Enriched	254	US	97%	97%	82%	97%
Pooled study	Enriched	690	EU & US	92%	90%	82%	90%

Leading advanced precancerous lesion sensitivity

CRC sensitivity



Advanced Adenoma sensitivity



* >10,000 subjects screening studies

Pipeline Development – Next-generation Pancreatic Cancer Detection

AN EARLY DETECTION PANCREATIC CANCER SCREENING TEST based on real-time PCR-based detection of biomarkers in stool samples

In early research stage



- As GenX individuals age into their 40s and 50s they become part of the age group recommended to begin testing for CRC ¹

Potential combo test with ColoAlert®

- Research program supported by a grant from Germany's Federal Ministry for Education and Research



World renowned advanced bio-analytics platform company

Pancreatic Cancer Blood-Test:

- Mainz has partnered with Liquid Biosciences to develop the next-generation detection test for pancreatic cancer
- We have entered into a license and option agreement with Liquid Biosciences to access novel mRNA biomarkers for early detection of pancreatic cancer via blood test
- Independent validation of the algorithm-biomarker combination showed 95% sensitivity and 98% specificity

¹ American Cancer Society (ACS) - Updated their guidelines in 2018 to recommend starting CRC screening at age 45.

Leadership Team, Board members and advisors



Guido Baechler
CEO, Director



William Caragol
CFO



Dr. Chris Von Törne
COO



Tarrin Khairi-Taraki
VP Commercial



Dr. Heiner Dreissmann
Chairman & non-Executive Director



Hans Hekland
Director



Gregory Tibbitts
Director

Clinical & Strategic advisors



Dr. Michele Pedrocchi
Strategic Advisor



Dr. Jay Wohlgemuth
Clinical Advisor



Dr. Kim Turgeon
Clinical Advisor



Dr. Soren Thestrup-Nielsen
Clinical Advisor



Dr. Timothy Wang
Clinical Advisor



Dr. Matthias Dollinger
Clinical Advisor

Summary Financial Data - Condensed

(unaudited), in \$	Six Months Ended June 30	
	2025	2024
REVENUE		
ColoAlert® Revenue	\$286,717	\$520,773
Cost of Revenue	97,128	201,735
GROSS PROFIT	189,589	319,038
OPERATING EXPENSES		
	66%	61%
Research and Development	3,055,088	3,242,622
Sales and Marketing	2,349,005	2,361,105
General and Administration	2,876,845	4,522,639
TOTAL OPERATING EXPENSES	8,280,938	10,126,366
NET LOSS	(8,344,211)	(11,023,762)
NON-CASH ADJUSTMENTS TO NET LOSS	1,940,517	2,218,072
ADJUSTED EBITDA	\$(6,403,694)	\$(8,805,690)
BALANCE SHEET DATA:	June 30, 2025	December 31, 2024
Cash Balance	\$1,911,069	\$6,235,670
Total Debt	\$1,620,782	\$2,125,254
Stockholders' Equity	\$2,522,349	\$6,046,543

Capitalization:

Nasdaq Ticker: MYNZ

Basic Shares O/S : 5,412,853 ⁽ⁱ⁾

Basic and PFW O/S : 7,872,075 ⁽ⁱ⁾

Fully Diluted Shares O/S: 18,506,452 ⁽ⁱ⁾



(i) As of September 30, 2025

Investment Highlights



Highly-differentiated
flagship product (ColoAlert®)

Significant market opportunity



Disruptive, decentralized business
model

Developing next-gen product



Strong intellectual
property position

Strong team



Executed milestones to
accelerate commercial roll-out



THANK YOU



MAINZBIOMED

INVESTOR PRESENTATION

Mainz Biomed N.V.
Robert-Koch-Straße 50
55129 Mainz, Germany

Tel: +49 (0) 6131 / 55428-60
Inquiries: info@mainzbiomed.com
it@mainzbiomed.com